Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

<div>Long-term tracking of HbA1c-related data; HbA1c: hemoglobin A1c; DPG: dapagliflozin; EPG: empagliflozin. (a) Proportion of subjects that reached HbA1c&lt; 6.5% (DPG), HbA1c 6.5~6.9% (DPG), HbA1c&lt; 6.5% (EPG), and HbA1c 6.5~6.9% (EPG) at 6, 12, 18, 24, 30, and 36 months. (b) Box plots indicating the HbA1c values compared to baseline levels after 6, 12, 18, 24, 30, and 36 months of treatment. (c) Proportion of subjects with a range of HbA1c values at 0 and 36 months. Range of HbA1c values by bars: &lt; 7.0%, 7%~7.9%, 8%~8.9%, &gt; 9%.</div>

Journal of Diabetes Research

fig2

Figure 2

Figure 2: Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes 

Figure 2 | Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes 